144 related articles for article (PubMed ID: 12751274)
1. Pharmacoscintigraphic assessment of the regional drug absorption of the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240, in healthy volunteers.
Martin NE; Collison KR; Martin LL; Tardif S; Wilding I; Wray H; Barrett JS
J Clin Pharmacol; 2003 May; 43(5):529-38. PubMed ID: 12751274
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of M100240 and MDL 100,173, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy young and elderly volunteers.
Emmons GT; Argenti R; Martin LL; Martin NE; Jensen BK
J Clin Pharmacol; 2004 Aug; 44(8):901-5. PubMed ID: 15286094
[TBL] [Abstract][Full Text] [Related]
3. The effect of food on the pharmacokinetics of a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240.
Cirillo I; Martin NE; Brennan B; Barrett JS
J Clin Pharmacol; 2004 Dec; 44(12):1379-84. PubMed ID: 15545308
[TBL] [Abstract][Full Text] [Related]
4. Mass balance study of [14C]M100240, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy male subjects.
Shah B; Emmons G; Rohatagi S; Martin NE; Jensen BK
Am J Ther; 2003; 10(5):356-62. PubMed ID: 12975720
[TBL] [Abstract][Full Text] [Related]
5. Optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240.
Pfister M; Martin NE; Haskell LP; Barrett JS
J Clin Pharmacol; 2004 Jun; 44(6):621-31. PubMed ID: 15145970
[TBL] [Abstract][Full Text] [Related]
6. No clinically relevant CYP3A induction with the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240.
Martin NE; Howell SR; Martin LL; Cirillo I; Barrett JS
J Clin Pharmacol; 2004 Apr; 44(4):379-87. PubMed ID: 15051745
[TBL] [Abstract][Full Text] [Related]
7. Assessment of levetiracetam bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy: Open-label, single-dose, randomized, four-way crossover study in healthy male volunteers.
Stockis A; Sargentini-Maier ML; Otoul C; Connor A; Wilding I; Wray H
Clin Ther; 2010 Sep; 32(10):1813-21. PubMed ID: 21194605
[TBL] [Abstract][Full Text] [Related]
8. Site-specific absorption of M100240 and MDL 100,173 in rats evaluated using Sweetana-Grass diffusion chamber technology.
Hwang KK; Jiang L; Ren Y; Martin LL; Martin NE
J Pharmacol Toxicol Methods; 2002; 48(2):97-101. PubMed ID: 14565566
[TBL] [Abstract][Full Text] [Related]
9. An oral human drug absorption study to assess the impact of site of delivery on the bioavailability of bevirimat.
Connor A; Evans P; Doto J; Ellis C; Martin DE
J Clin Pharmacol; 2009 May; 49(5):606-12. PubMed ID: 19304891
[TBL] [Abstract][Full Text] [Related]
10. Bioavailability of repeated oral administration of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase in healthy volunteers.
Rousso P; Buclin T; Nussberger J; Brunner-Ferber F; Brunner HR; Biollaz J
Eur J Clin Pharmacol; 2000 Jan; 55(10):749-54. PubMed ID: 10663454
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans.
Zhu T; Ansquer JC; Kelly MT; Sleep DJ; Pradhan RS
J Clin Pharmacol; 2010 Aug; 50(8):914-21. PubMed ID: 20145261
[TBL] [Abstract][Full Text] [Related]
12. Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects.
Henney HR; Shah J
Clin Ther; 2007 Apr; 29(4):661-9. PubMed ID: 17617289
[TBL] [Abstract][Full Text] [Related]
13. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin.
Mück W; Ritter W; Ochmann K; Unger S; Ahr G; Wingender W; Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Jun; 35(6):255-60. PubMed ID: 9208342
[TBL] [Abstract][Full Text] [Related]
14. Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible.
Reddy MB; Connor A; Brennan BJ; Morcos PN; Zhou A; McLawhon P; Fretland A; Evans P; Smith P; Tran JQ
Biopharm Drug Dispos; 2011 Jul; 32(5):261-75. PubMed ID: 21660978
[TBL] [Abstract][Full Text] [Related]
15. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
[TBL] [Abstract][Full Text] [Related]
16. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
[TBL] [Abstract][Full Text] [Related]
17. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
[TBL] [Abstract][Full Text] [Related]
18. Assessment of tacrolimus absorption from the human intestinal tract: open-label, randomized, 4-way crossover study.
Tsunashima D; Kawamura A; Murakami M; Sawamoto T; Undre N; Brown M; Groenewoud A; Keirns JJ; Holman J; Connor A; Wylde H; Wilding I; Ogawara K; Sako K; Higaki K; First R
Clin Ther; 2014 May; 36(5):748-59. PubMed ID: 24680768
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance.
Weinling E; McDougall S; Andre F; Bianchetti G; Dubruc C
Fundam Clin Pharmacol; 2006 Aug; 20(4):397-403. PubMed ID: 16867025
[TBL] [Abstract][Full Text] [Related]
20. The assessment of human regional drug absorption of free acid and sodium salt forms of acipimox, in healthy volunteers, to direct modified release formulation strategy.
Menon R; Cefali E; Wilding I; Wray H; Connor A
Biopharm Drug Dispos; 2009 Dec; 30(9):508-16. PubMed ID: 19798634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
